Pfizer Inc. ($PFE) Stock Forecast: Down 6.3% Today

What is Pfizer Inc.?

Pfizer (NYSE: PFE) is a prominent pharmaceutical company recognized for its innovations in healthcare, particularly in the field of vaccines and oncology. Recent developments within the healthcare sector have influenced the overall market sentiment.

Why is Pfizer Inc. going down?

PFE stock is down 6.3% on Nov 15, 2024 17:41

• Today, Pfizer's stock showed a decline.
• The appointment of a vaccine skeptic, Robert F. Kennedy Jr., by President-elect Donald Trump to lead the HHS has created doubt and uncertainty in the market.
• While Pfizer has seen success in oncology treatments, the focus on vaccine-related news and the prevailing sentiment in the healthcare industry have had a negative impact on the stock.
• Despite indications of bullish options trading towards Pfizer from well-resourced investors, suggesting a possible future upturn, the current market trend remains bearish due to external factors.

PFE Price Chart

PFE Technical Analysis

PFE News

Unpacking the Latest Options Trading Trends in Pfizer - Pfizer ( NYSE:PFE )

Deep-pocketed investors have adopted a bullish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

https://www.benzinga.com/insights/options/24/11/42011699/unpacking-the-latest-options-trading-trends-in-pfizer

Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS

President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.

https://www.zacks.com/stock/news/2370835/vaccine-stocks-fall-after-trump-selects-rfk-jr-to-lead-hhs

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Johnson & Johnson ( NYSE:JNJ )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs analyst David Roman initiated coverage on HealthEquity, Inc.

https://www.benzinga.com/24/11/42005399/this-johnson-here-are-top-5-initiations-for-friday

Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS

Shares of Moderna, Novavax, Pfizer, BioNTech and GSK closed lower on Thursday.

https://www.cnbc.com/2024/11/14/vaccine-maker-stocks-fall-as-trump-chooses-rfk-jr-to-lead-hhs.html

The Oncology Bet Is Already Paying Off For Pfizer - Pfizer ( NYSE:PFE )

With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc PFE reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December.

https://www.benzinga.com/markets/penny-stocks/24/11/41959650/the-oncology-bet-is-already-paying-off-for-pfizer

Trending Today

Helmerich & Payne Inc. ($HP) Stock Forecast: Up 5.1% Today

Williams-Sonoma Inc. (DE) ($WSM) Stock Forecast: Down 5.3% Today

Stellar ($XLM) Crypto Forecast: Down 5.9% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 8.0% Today

Optimism ($OP) Crypto Forecast: Up 25.0% Today

Litecoin ($LTC) Crypto Forecast: Up 5.1% Today

Natural Gas ($GAS) Commodity Forecast: Up 8.0% Today

dogwifhat ($WIF) Crypto Forecast: Up 5.5% Today

NetApp Inc. ($NTAP) Stock Forecast: Up 5.1% Today

Pfizer Inc. Price History

15.10.2024 - PFE Stock was down 7.4%

• Pfizer's stock faced significant downward pressure due to concerns surrounding the appointment of a vaccine skeptic to lead the HHS by President-elect Donald Trump.
• This development led to a bearish response in Pfizer's stock price and also impacted other vaccine makers like Moderna, Novavax, and BioNTech.
• Despite the recent decline, there may be an opportunity for investors to consider purchasing Pfizer's stock as it is currently oversold, with analysts increasing earnings estimates, suggesting a potential reversal in the stock's trend soon.

15.10.2024 - PFE Stock was down 6.3%

• Today, Pfizer's stock showed a decline.
• The appointment of a vaccine skeptic, Robert F. Kennedy Jr., by President-elect Donald Trump to lead the HHS has created doubt and uncertainty in the market.
• While Pfizer has seen success in oncology treatments, the focus on vaccine-related news and the prevailing sentiment in the healthcare industry have had a negative impact on the stock.
• Despite indications of bullish options trading towards Pfizer from well-resourced investors, suggesting a possible future upturn, the current market trend remains bearish due to external factors.

09.08.2024 - PFE Stock was up 2.3%

• The surge in Pfizer's stock was attributed to positive developments in the pharmaceutical industry, particularly related to competitors and collaborations, which increased investor confidence.
• Moderna's recent positive CHMP opinion and approval for an updated COVID-19 vaccine likely contributed to sector-wide optimism and benefitted Pfizer.
• Vaxcyte's vaccine study results, showing strong immune responses and reaching a record high, created a positive sentiment for vaccine-related companies like Pfizer.
• Pfizer's strategic clinical partnership with Acepodia to expedite development in autoimmune diseases indicated potential growth opportunities, driving up the stock price further.

09.09.2024 - PFE Stock was up 2.9%

• Pfizer's stock experienced a strong bullish movement today.
• The stock rose after receiving a $1 billion investment from activist investor Starboard Value, leading to optimism about a potential turnaround for the company.
• Additionally, Pfizer won a court battle in London, which may have boosted investor confidence in the company's future prospects.
• The news of the investment and legal victory likely contributed to the bullish market movement for Pfizer today.

29.09.2024 - PFE Stock was down 1.9%

• Despite reporting strong Q3 earnings and revenue beats, the market movement may have been influenced by profit-taking behavior from investors after a period of heightened demand for its COVID products.
• The heightened demand for Paxlovid and expectations of $10 billion in 2024 revenue from COVID products may have already been priced into the stock, leading to a sell-off post-earnings.
• The ongoing proxy battle with activist investor Starboard Value could have added uncertainty and pressure on the stock, contributing to the bearish movement.
• Investors might be closely monitoring Pfizer's non-COVID drug performance and the impact of new and acquired products on the company's future revenue growth, which could influence future market sentiment.

26.05.2024 - PFE Stock was down 3.6%

• The bearish movement in Pfizer's stock could be attributed to concerns raised by a recent meeting discussing vaccine recommendations, potentially impacting the company's vaccine sales and future prospects.
• The news of another company's RSV shot being more effective after 18 months, compared to Pfizer's lower effectiveness midway through a second RSV season, might have negatively influenced investor sentiment towards Pfizer's vaccine portfolio.
• Negative outcomes in the healthcare sector, like Pfizer, can sometimes lead to increased scrutiny and skepticism, impacting investor confidence and stock performance.
• The overall market trend of buying blue-chip stocks on the dip might have also contributed to Pfizer's stock decline, as investors may have shifted their focus towards other opportunities in the market, leading to a relative underperformance of Pfizer's stock.

13.01.2024 - PFE Stock was down 1.7%

• Today, Pfizer's stock exhibited a noticeable downward trend.
• Recent discussions within US companies regarding layoffs and cost management may have influenced the market's perception of Pfizer's stock.
• The incorporation of Pfizer in conversations about operational efficiency and expense management during earnings calls could have had an adverse effect on the stock's performance.
• The general market sentiment towards biotech stocks likely contributed to the bearish movement experienced by Pfizer's stock.

06.02.2024 - PFE Stock was up 5.2%

• Pfizer's stock saw a significant bullish surge following endorsements from prominent investors, highlighting its potential for growth and dividends.
• The positive sentiment was further fueled by Pfizer's resilience in the market, trading at a price similar to over a decade ago, making it an attractive opportunity for investors.
• Despite concerns raised by the WHO regarding resistance associated with one of Pfizer's HIV drugs, the overall market optimism and investor confidence in Pfizer's long-term prospects overshadowed these challenges.
• Analysts continue to view Pfizer as a strong buy, emphasizing its undervalued status and potential for substantial upside in the future, contributing to the bullish movement in the stock.

13.11.2023 - PFE Stock was down 7.1%

• The bearish movement in Pfizer's stock today can be attributed to several factors:
• 1. Disappointing sales of COVID-19 products: Pfizer's financial outlook for next year fell short of Wall Street expectations, primarily due to declining sales of COVID-19 treatments and vaccines. The shift from selling these products to governments to the commercial market has resulted in a significant decrease in revenue, causing investor concern.
• 2. Seagen guidance update: Pfizer's stock tumble steepened as Seagen, a company it recently acquired, provided a guidance update that disappointed investors. The expected financial impact from this transaction may have contributed to the bearish movement.
• 3. Lower profit expectations: Pfizer's projected per-share earnings for next year are well below what many had anticipated. This discrepancy between Pfizer's profit expectations and Wall Street projections could have negatively impacted investor sentiment.
• 4. Market competition and acquisitions: The acquisition of Seagen and its potential contribution to Pfizer's revenue by 2030 may have raised concerns about market competition and the company's ability to maintain its growth trajectory.
• Overall, the bearish movement in Pfizer's stock today can be attributed to disappointing sales of COVID-19 products, a guidance update from Seagen, lower profit expectations, and market competition.

11.06.2024 - PFE Stock was up 1.3%

• Pfizer's bullish movement today can be attributed to the positive news regarding the advancement of its once-daily weight-loss pill, danuglipron, which shows promise in the ongoing Phase 1 study. This development indicates potential future revenue streams and market expansion for the company.
• The company's decision to move forward with the once-daily version of the weight-loss pill, despite previous setbacks, demonstrates Pfizer's commitment to innovation and addressing market needs.
• The search for a new Chief Scientific Officer following Dr. Mikael Dolsten's departure may have initially caused some uncertainty in the market, but the overall positive news regarding product development likely overshadowed this aspect, contributing to the bullish movement in the stock.

30.06.2024 - PFE Stock was down 2.0%

• Despite Pfizer delivering robust earnings with revenue exceeding expectations and achieving its first revenue growth since the COVID peak in 2022, the stock encountered a bearish trend.
• The market's response may have been influenced by the substantial decrease in reported net income, showing a 98% year-over-year decline.
• Investors could be expressing worries about Pfizer's dependency on COVID-related products, as the company faces a sharp revenue decline in that particular segment.
• Despite the overall positive market sentiment and Pfizer's increased annual profit forecast driven by strong sales of cancer and heart drugs, the negative impact of the severe net income decline on the stock price was not overcome.

30.06.2024 - PFE Stock was up 1.4%

• Pfizer's recent market movement is linked to its first sales growth since the onset of the pandemic, especially in the field of cancer treatment, demonstrating its capacity to adapt and innovate in evolving market conditions.
• Strong Q2 results, surpassing earnings per share and revenue projections, likely bolstered investor trust in the company's performance and future potential.
• Amid declines in tech stocks and surges in financials and energy stocks, Pfizer's steadfastness and emphasis on areas like cancer treatment resonated with investors, sparking increased interest and a bullish trend for the stock.